All In Biotech

Drug Trial Radar · NCT06814496

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

May 2030

Study completion May 2030

Sponsor

Lead sponsor
University of ArizonaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amgen
First posted
Feb 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. III) If sequential tarlatamab and radiation is not deemed safe, we would allow for continued enrollment to assess efficacy of drug sans radiation treatment, enriching for tumors not of small cell lung cancer histology and allowing for patients without sites amenable to RT. A nested phase II study will attempt to assess for ORR and safety of study intervention amongst tumors not of small cell lung cancer histology.

Conditions

  • Melanoma
  • Medullary Thyroid Cancer
  • Sinonasal Undifferentiated Carcinoma
  • Esthesioneuroblastoma
  • Bladder Cancer
  • Testicular Cancer
  • Glioblastoma Multiforme
  • Cervical Cancer
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • Non Small Cell Lung Cancer
  • Merkel Cell Carcinoma

Interventions

  • TarlatamabDrug

    Tarlatamab will be administered at a step-up dose of 1mg on Cycle 1 Day 1 and then 10 mg on Cycle 1 Day 8 and Cycle 1 Day 15 and every 2 weeks thereafter. For cycle 2 onwards, tarlatamab infusion will occur every 2 weeks on days 1 and 15 of each cycle.

  • Concurrent Radiation TherapyRadiation

    Standard of care RT can begin as early as Cycle 1 Day 16 and as late as Cycle 2 Day 28, assuming there is no ongoing CRS (extracranial)/ICANS (cranial).

  • Sequential Radiation therapyRadiation

    Standard of care radiation therapy can occur prior to Cycle 1 Day 1 (if radiation treatment is completed \<7 days prior to the start of tarlatamab) or be interdigitated with tarlatamab with a 7-day washout between RT and infusion, with RT to begin as early as Cycle 1 Day 22 and as late as cycle 2 Day 28, assuming no ongoing CRS (extracranial)/ICANS (cranial).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab.Time frame: Until radiographic or disease progression or up to 24 months, whichever is earlier.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Arizona Cancer Center at UMC North/University Medical Center

    Tucson, Arizona · Recruiting

  • University of Washington Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.